Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$3.00
-0.25-7.69%
At close: -
$2.99
-0.00890-0.30%
After Hours: Apr 4, 7:59 PM EDT
Comments
Loading...
Iovance Biotherapeutics Analyst Ratings and Price Targets | NASDAQ:IOVA | Benzinga
Iovance Biotherapeutics Inc has a consensus price target of $19.76 based on the ratings of 18 analysts. The high is $34 issued by Baird on April 7, 2022. The low is $6 issued by Piper Sandler on February 28, 2025. The 3 most-recent analyst ratings were released by Truist Securities, Goldman Sachs, and Chardan Capital on March 3, 2025, respectively. With an average price target of $21.33 between Truist Securities, Goldman Sachs, and Chardan Capital, there's an implied 613.23% upside for Iovance Biotherapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Truist Securities
Goldman Sachs
Chardan Capital
Baird
Piper Sandler
1calculated from analyst ratings
Analyst Ratings for Iovance Biotherapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/03/2025 | Buy Now | 401.49% | Truist Securities | Asthika Goonewardene40% | $25 → $15 | Maintains | Buy | Get Alert |
| 03/03/2025 | Buy Now | 535.22% | Goldman Sachs | Andrea Tan40% | $22 → $19 | Maintains | Buy | Get Alert |
| 03/03/2025 | Buy Now | 902.98% | Chardan Capital | Geulah Livshits44% | $34 → $30 | Maintains | Buy | Get Alert |
| 02/28/2025 | Buy Now | 568.65% | Baird | Michael Ulz59% | $24 → $20 | Maintains | Outperform | Get Alert |
| 02/28/2025 | Buy Now | 100.6% | Piper Sandler | Joseph Catanzaro41% | $7.5 → $6 | Maintains | Neutral | Get Alert |
| 02/28/2025 | Buy Now | 969.84% | HC Wainwright & Co. | Joseph Pantginis44% | $32 → $32 | Reiterates | Buy → Buy | Get Alert |
| 01/31/2025 | Buy Now | 150.74% | Piper Sandler | Joseph Catanzaro41% | $10 → $7.5 | Maintains | Neutral | Get Alert |
| 11/06/2024 | Buy Now | 969.84% | HC Wainwright & Co. | Joseph Pantginis44% | $32 → $32 | Reiterates | Buy → Buy | Get Alert |
| 10/24/2024 | Buy Now | 468.35% | UBS | David Dai26% | → $17 | Initiates | → Buy | Get Alert |
| 08/12/2024 | Buy Now | 969.84% | HC Wainwright & Co. | Joseph Pantginis44% | $32 → $32 | Reiterates | Buy → Buy | Get Alert |
| 07/29/2024 | Buy Now | 234.33% | Piper Sandler | Joseph Catanzaro41% | $19 → $10 | Downgrade | Overweight → Neutral | Get Alert |
| 06/28/2024 | Buy Now | 969.84% | HC Wainwright & Co. | Joseph Pantginis44% | $32 → $32 | Reiterates | Buy → Buy | Get Alert |
| 06/20/2024 | Buy Now | 668.95% | JMP Securities | Reni Benjamin45% | $25 → $23 | Maintains | Market Outperform | Get Alert |
| 06/03/2024 | Buy Now | 969.84% | HC Wainwright & Co. | Joseph Pantginis44% | $32 → $32 | Reiterates | Buy → Buy | Get Alert |
| 05/31/2024 | Buy Now | 969.84% | HC Wainwright & Co. | Joseph Pantginis44% | $32 → $32 | Reiterates | Buy → Buy | Get Alert |
| 05/24/2024 | Buy Now | 969.84% | HC Wainwright & Co. | Joseph Pantginis44% | $32 → $32 | Reiterates | Buy → Buy | Get Alert |
| 05/10/2024 | Buy Now | 969.84% | HC Wainwright & Co. | Joseph Pantginis44% | $32 → $32 | Reiterates | Buy → Buy | Get Alert |
| 03/14/2024 | Buy Now | 535.22% | Piper Sandler | Joseph Catanzaro41% | $18 → $19 | Maintains | Overweight | Get Alert |
| 03/07/2024 | Buy Now | 769.25% | Truist Securities | Asthika Goonewardene40% | $17 → $26 | Maintains | Buy | Get Alert |
| 03/04/2024 | Buy Now | 969.84% | HC Wainwright & Co. | Joseph Pantginis44% | $32 → $32 | Reiterates | Buy → Buy | Get Alert |
| 03/01/2024 | Buy Now | 735.81% | Wells Fargo | Yanan Zhu35% | $22 → $25 | Maintains | Overweight | Get Alert |
| 02/29/2024 | Buy Now | 969.84% | HC Wainwright & Co. | Joseph Pantginis44% | $32 → $32 | Reiterates | Buy → Buy | Get Alert |
| 02/29/2024 | Buy Now | 602.08% | Goldman Sachs | Andrea Tan40% | $19 → $21 | Maintains | Buy | Get Alert |
| 02/29/2024 | Buy Now | 635.52% | Barclays | Peter Lawson41% | $18 → $22 | Maintains | Overweight | Get Alert |
| 02/21/2024 | Buy Now | 535.22% | Goldman Sachs | Andrea Tan40% | $13 → $19 | Maintains | Buy | Get Alert |
| 02/20/2024 | Buy Now | 735.81% | JMP Securities | Reni Benjamin45% | $18 → $25 | Maintains | Market Outperform | Get Alert |
| 02/20/2024 | Buy Now | 635.52% | Wells Fargo | Yanan Zhu35% | $17 → $22 | Maintains | Overweight | Get Alert |
| 02/20/2024 | Buy Now | 535.22% | Goldman Sachs | Andrea Tan40% | $13 → $19 | Maintains | Buy | Get Alert |
| 02/20/2024 | Buy Now | 501.79% | Piper Sandler | Joseph Catanzaro41% | $14 → $18 | Maintains | Overweight | Get Alert |
| 02/20/2024 | Buy Now | 1036.71% | Chardan Capital | Geulah Livshits44% | $29 → $34 | Maintains | Buy | Get Alert |
| 12/27/2023 | Buy Now | 836.11% | HC Wainwright & Co. | Joseph Pantginis44% | $38 → $28 | Maintains | Buy | Get Alert |
| 12/27/2023 | Buy Now | 468.35% | Truist Securities | Asthika Goonewardene40% | $17 → $17 | Reiterates | Buy → Buy | Get Alert |
| 11/20/2023 | Buy Now | 301.19% | Goldman Sachs | Andrea Tan40% | → $12 | Initiates | → Buy | Get Alert |
| 11/08/2023 | Buy Now | 836.11% | HC Wainwright & Co. | Joseph Pantginis44% | $38 → $28 | Maintains | Buy | Get Alert |
| 09/18/2023 | Buy Now | 501.79% | Barclays | Peter Lawson41% | $40 → $18 | Maintains | Overweight | Get Alert |
| 09/15/2023 | Buy Now | 468.35% | Truist Securities | Asthika Goonewardene40% | → $17 | Reiterates | Buy → Buy | Get Alert |
| 09/15/2023 | Buy Now | 902.98% | Mizuho | Mara Goldstein55% | → $30 | Reiterates | Buy → Buy | Get Alert |
| 09/15/2023 | Buy Now | 735.81% | Stifel | Benjamin Burnett43% | → $25 | Reiterates | Buy → Buy | Get Alert |
| 09/15/2023 | Buy Now | 501.79% | JMP Securities | Reni Benjamin45% | → $18 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 09/15/2023 | Buy Now | 1170.44% | HC Wainwright & Co. | Joseph Pantginis44% | → $38 | Reiterates | Buy → Buy | Get Alert |
| 09/13/2023 | Buy Now | 735.81% | Stifel | Benjamin Burnett43% | $27 → $25 | Maintains | Buy | Get Alert |
| 08/17/2023 | Buy Now | 501.79% | JMP Securities | Reni Benjamin45% | → $18 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 08/16/2023 | Buy Now | 869.54% | Chardan Capital | Geulah Livshits44% | $29 → $29 | Reiterates | Buy → Buy | Get Alert |
| 08/09/2023 | Buy Now | 869.54% | Chardan Capital | Geulah Livshits44% | → $29 | Reiterates | Buy → Buy | Get Alert |
| 08/09/2023 | Buy Now | 1170.44% | HC Wainwright & Co. | Joseph Pantginis44% | → $38 | Reiterates | Buy → Buy | Get Alert |
| 07/11/2023 | Buy Now | 468.35% | Truist Securities | Asthika Goonewardene40% | → $17 | Reiterates | Buy → Buy | Get Alert |
| 07/11/2023 | Buy Now | 869.54% | Chardan Capital | Geulah Livshits44% | → $29 | Reiterates | Buy → Buy | Get Alert |
| 07/10/2023 | Buy Now | 1170.44% | HC Wainwright & Co. | Joseph Pantginis44% | → $38 | Reiterates | Buy → Buy | Get Alert |
| 06/27/2023 | Buy Now | 902.98% | Mizuho | Mara Goldstein55% | → $30 | Reiterates | Buy → Buy | Get Alert |
| 06/16/2023 | Buy Now | 902.98% | Mizuho | Mara Goldstein55% | → $30 | Reiterates | Buy → Buy | Get Alert |
| 06/15/2023 | Buy Now | 1170.44% | HC Wainwright & Co. | Joseph Pantginis44% | → $38 | Reiterates | Buy → Buy | Get Alert |
| 06/05/2023 | Buy Now | 501.79% | JMP Securities | Reni Benjamin45% | → $18 | Reiterates | → Market Outperform | Get Alert |
| 05/30/2023 | Buy Now | 468.35% | Wells Fargo | Yanan Zhu35% | $11 → $17 | Upgrade | Equal-Weight → Overweight | Get Alert |
| 05/30/2023 | Buy Now | 501.79% | JMP Securities | Reni Benjamin45% | → $18 | Reinstates | Market Outperform → Market Perform | Get Alert |
| 05/30/2023 | Buy Now | 702.38% | Stifel | Benjamin Burnett43% | $21 → $24 | Maintains | Buy | Get Alert |
| 05/30/2023 | Buy Now | 869.54% | Chardan Capital | Geulah Livshits44% | → $29 | Reiterates | Buy → Buy | Get Alert |
| 05/30/2023 | Buy Now | 1170.44% | HC Wainwright & Co. | Joseph Pantginis44% | → $38 | Reiterates | Buy → Buy | Get Alert |
| 05/28/2023 | Buy Now | 602.08% | Stifel | Benjamin Burnett43% | $21 → $21 | Maintains | Buy | Get Alert |
| 05/23/2023 | Buy Now | 668.95% | Baird | Michael Ulz59% | $20 → $23 | Maintains | Outperform | Get Alert |
| 05/11/2023 | Buy Now | 602.08% | Stifel | Benjamin Burnett43% | → $21 | Maintains | Buy | Get Alert |
| 05/10/2023 | Buy Now | 568.65% | Baird | Michael Ulz59% | $25 → $20 | Maintains | Outperform | Get Alert |
| 03/27/2023 | Buy Now | 267.76% | Wells Fargo | Yanan Zhu35% | → $11 | Assumes | → Equal-Weight | Get Alert |
| 03/27/2023 | Buy Now | 1170.44% | HC Wainwright & Co. | Joseph Pantginis44% | → $38 | Reiterates | → Buy | Get Alert |
| 03/06/2023 | Buy Now | 267.76% | Wells Fargo | Adam Shine63% | $14 → $11 | Maintains | Equal-Weight | Get Alert |
| 03/01/2023 | Buy Now | 401.49% | Oppenheimer | Mark Breidenbach47% | $25 → $15 | Maintains | Outperform | Get Alert |
| 03/01/2023 | Buy Now | 869.54% | Chardan Capital | Geulah Livshits44% | → $29 | Reiterates | → Buy | Get Alert |
| 03/01/2023 | Buy Now | 1170.44% | HC Wainwright & Co. | Joseph Pantginis44% | → $38 | Reiterates | → Buy | Get Alert |
| 01/27/2023 | Buy Now | 368.06% | Piper Sandler | Joseph Catanzaro41% | $11 → $14 | Upgrade | Neutral → Overweight | Get Alert |
| 01/24/2023 | Buy Now | 468.35% | Truist Securities | Asthika Goonewardene40% | $16 → $17 | Maintains | Buy | Get Alert |
| 12/09/2022 | Buy Now | 100.6% | Goldman Sachs | Madhu Kumar73% | $20 → $6 | Downgrade | Buy → Neutral | Get Alert |
| 12/09/2022 | Buy Now | 100.6% | Benchmark | Madhu Kumar73% | $20 → $6 | Downgrade | Buy → Neutral | Get Alert |
| 11/21/2022 | Buy Now | 602.08% | JMP Securities | Reni Benjamin45% | $25 → $21 | Maintains | Market Outperform | Get Alert |
| 11/21/2022 | Buy Now | 267.76% | Piper Sandler | Joseph Catanzaro41% | $13 → $11 | Maintains | Neutral | Get Alert |
| 11/21/2022 | Buy Now | 869.54% | Chardan Capital | Geulah Livshits44% | $30 → $29 | Maintains | Buy | Get Alert |
| 11/18/2022 | Buy Now | 1170.44% | HC Wainwright & Co. | Joseph Pantginis44% | $43 → $38 | Maintains | Buy | Get Alert |
| 10/31/2022 | Buy Now | — | Guggenheim | Kelsey Goodwin30% | — | Initiates | → Neutral | Get Alert |
| 08/10/2022 | Buy Now | 702.38% | Stifel | Benjamin Burnett43% | → $24 | Maintains | Buy | Get Alert |
| 08/05/2022 | Buy Now | 735.81% | Baird | Michael Ulz59% | $34 → $25 | Maintains | Outperform | Get Alert |
| 07/01/2022 | Buy Now | 501.79% | Goldman Sachs | Madhu Kumar73% | $64 → $18 | Maintains | Buy | Get Alert |
| 05/27/2022 | Buy Now | 334.62% | Stifel | Benjamin Burnett43% | $26 → $13 | Maintains | Buy | Get Alert |
| 05/27/2022 | Buy Now | 802.68% | Oppenheimer | Mark Breidenbach47% | $31 → $27 | Maintains | Outperform | Get Alert |
| 05/27/2022 | Buy Now | 936.41% | Chardan Capital | Geulah Livshits44% | $44 → $31 | Maintains | Buy | Get Alert |
| 05/27/2022 | Buy Now | 334.62% | Piper Sandler | Joseph Catanzaro41% | $20 → $13 | Maintains | Neutral | Get Alert |
| 05/24/2022 | Buy Now | 2039.68% | Goldman Sachs | Madhu Kumar73% | $79 → $64 | Maintains | Buy | Get Alert |
| 05/06/2022 | Buy Now | 769.25% | Stifel | Benjamin Burnett43% | → $26 | Maintains | Buy | Get Alert |
| 04/07/2022 | Buy Now | 1036.71% | Baird | Colleen Kusy34% | $30 → $34 | Maintains | Outperform | Get Alert |
FAQ
What is the target price for Iovance Biotherapeutics (IOVA) stock?
The latest price target for Iovance Biotherapeutics (NASDAQ:IOVA) was reported by Truist Securities on March 3, 2025. The analyst firm set a price target for $15.00 expecting IOVA to rise to within 12 months (a possible 401.49% upside). 17 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Iovance Biotherapeutics (IOVA)?
The latest analyst rating for Iovance Biotherapeutics (NASDAQ:IOVA) was provided by Truist Securities, and Iovance Biotherapeutics maintained their buy rating.
When was the last upgrade for Iovance Biotherapeutics (IOVA)?
The last upgrade for Iovance Biotherapeutics Inc happened on May 30, 2023 when Wells Fargo raised their price target to $17. Wells Fargo previously had an equal-weight for Iovance Biotherapeutics Inc.
When was the last downgrade for Iovance Biotherapeutics (IOVA)?
The last downgrade for Iovance Biotherapeutics Inc happened on July 29, 2024 when Piper Sandler changed their price target from $19 to $10 for Iovance Biotherapeutics Inc.
When is the next analyst rating going to be posted or updated for Iovance Biotherapeutics (IOVA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Iovance Biotherapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Iovance Biotherapeutics was filed on March 3, 2025 so you should expect the next rating to be made available sometime around March 3, 2026.
Is the Analyst Rating Iovance Biotherapeutics (IOVA) correct?
While ratings are subjective and will change, the latest Iovance Biotherapeutics (IOVA) rating was a maintained with a price target of $25.00 to $15.00. The current price Iovance Biotherapeutics (IOVA) is trading at is $2.99, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.